Treatment with supramaximal cholecystokinin (CCK) or its analogue cerulein induces pancreatitis in rodents, which has been studied extensively since the pathological and histological presentation of this model is similar to the early phase of AP in human [191]. The gene discussed is CCK; the disease is pancreatitis.